WOODCLIFF LAKE - Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25.

New data to be presented on lenvatinib (marketed as LENVIMA) include two post-hoc analyses from the Phase 3 REFLECT trial (Study 304): one investigating overall survival according to subsequent anticancer procedure received by patients with unresectable hepatocellular carcinoma (HCC) who were either treated with lenvatinib or sorafenib in the first line (Abstract #520), and the second assessing the relationship between baseline liver function and efficacy and safety outcomes with lenvatinib (Abstract #524). Early results from a Phase 1b study evaluating lenvatinib plus nivolumab (Abstract #513) in patients with unresectable HCC will also be presented.

'At Eisai, we continue to study our medicines and follow the science to uncover new insights that may improve cancer care for the patients we aim to serve,' said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. 'Through our research, we hope to enhance our understanding of the potential of our medicines for people living with unresectable hepatocellular carcinoma, and we look forward to sharing our latest findings with the oncology community at this year's GI Cancers Symposium.'

This release discusses investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

About Eisai

Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as 'giving first thought to patients and their families and to increasing the benefits health care provides,' which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

Contact:

Michele Randazzo

Tel: 201-746-2979

Email: michelerandazzo@eisai.com

(C) 2020 Electronic News Publishing, source ENP Newswire